Cmed Appoints New Global Head of Commercial Operations

Written by Cmed

Cmed, an innovative technology-led CRO, announced today the appointment of David Holloway as its new Global Head of Commercial Operations. His appointment strengthens Cmed’s management team as it accelerates new developments and opportunities for encapsia®, the first App based new generation clinical data suite available which has already been proven and used to successfully complete studies.

In this role, Mr. Holloway will help drive the continued commercialization of encapsia®, providing leadership and strategic guidance. He will also ensure greater synergy between Cmed’s marketing, sales and communication activities, as well as further develop the company’s sales propositions and commercial opportunities in terms of partnerships and collaborations.

“We are extremely pleased to welcome David Holloway to Cmed,” said Dr. David Connelly, Cmed’s CEO. “He joins at a pivotal time for Cmed as we advance our already considerable expertise in the delivery of clinical trials with encapsia®. His broad and extensive expertise and experience in the industry will play an essential part in helping us to define and execute our strategy for encapsia® and will be very valuable in driving our plans for future growth”.

Mr. Holloway added “I’m delighted to join Cmed at such an exciting time in the advancement of encapsia®. I have been really impressed with the company’s mission and its focus on applying technological innovation to change the way clinical trials are conducted. I am excited to be part of a team that will better enable those involved in running clinical trials to capture, monitor and manage their data in ways I have not seen possible before.”

Mr. Holloway joins Cmed with nearly 30 years multi–national experience in Clinical Operations, General Management, Marketing and Communications, Business Development and Project and Contract Management, gained in organizations across the healthcare sector. Prior to Cmed, he has held senior positions in Pharmaceutical Companies and Clinical Research Organizations in Europe and the US and has also held management posts at the Royal National Orthopaedic Hospital and the UK Regulatory Agency.